{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}],"title":"Received hematopoietic cell transplantation"},{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}],"title":"Did not receive hematopoietic cell transplantation"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Frequency at which the participants received a hematopoietic cell transplantation (HCT)","groups":[{"description":"Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine (AZC): Given IV or SC\n\nDecitabine: Given IV or SC\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm A (Decitabine or Azacitidine)"},{"description":"Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm B (Induction-like Chemotherapy Regimen)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Number of Participants Who Received a Hematopoietic Cell Transplantation (HCT).","type":"SECONDARY","unitOfMeasure":"Participants"}